The potential link between atherosclerosis and the 5-lipoxygenase pathway: Investigational agents with new implications for the cardiovascular field

Expert Opinion on Investigational Drugs

Volumn 16, Issue 12, 2007, Pages 1879-1893

  Whatling, Carl ^a   McPheat, William ^a   Herslöf, Margareta ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

5 lipoxygenase; Acute coronary syndromes; Atherosclerosis; Cardiovascular disease; Five lipoxygenase activating protein; Leukotriene A4 hydrolase; Leukotriene receptors; Leukotrienes; Myocardial infarction; Stroke

Indexed keywords

1 ETHYL 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 2 QUINOLONE; 2 (3 BENZYL 4 HYDROXYCHROMAN 7 YL) 4 TRIFLUOROMETHYLBENZOIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 (2 QUINOLINYLMETHOXY) 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; 6 [[3 FLUORO 5 (3,4,5,6 TETRAHYDRO 4 METHOXY 2H PYRAN 4 YL)]PHENOXYMETHYL] 1 METHYL 2 QUINOLONE; AM 103; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ATRELEUTON; AZLAIRE; BIIL 284; BW A 4C; CP 195542; DG 031; DG 051; DM 051; ETALOCIB; GELATINASE A; GELATINASE B; LEUKOTRIENE A4; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXIN; LIPOXYGENASE INHIBITOR; MONTELUKAST; N [3 (3 PHENOXYPHENYL)ALLYL]ACETOHYDROXAMIC ACID; PEPTIDOLEUKOTRIENE; PRANLUKAST; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIA 2291; ZAFIRLUKAST; ZILEUTON; NEW DRUG;

ACUTE CORONARY SYNDROME; ASTHMA; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BIOSYNTHESIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMICAL STRUCTURE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART INFARCTION; HUMAN; INFLAMMATION; INNATE IMMUNITY; LIVER TOXICITY; NONHUMAN; PANCREAS TUMOR; PATIENT MONITORING; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; TREATMENT INDICATION; ANIMAL; CHEMISTRY; DRUG ANTAGONISM; ENZYMOLOGY; METABOLISM;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; HUMANS; LIPOXYGENASE INHIBITORS;

EID: 39549092191     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.12.1879     Document Type: Review

References (106)

1. LIBBY P: The forgotten majority: unfinished business in cardiovascular risk reduction. J. Am. Coll. Cardiol. (2005) 46(7):1225-1228.
2. HANSSON GK: Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. (2005) 352(16):1685-1695.
3. LIBBY P: Atherosclerosis: disease biology affecting the coronary vasculature. Am. J. Cardiol. (2006) 98(12A):Q3-Q9.
4. NAGHAVI M, LIBBY P, FALK E et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 108(15):1772-1778.
5. NAGHAVI M, LIBBY P, FALK E et al.: From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 108(14):1664-1672.
6. MACH F: New anti-inflammatory agents to reduce atherosclerosis. Arrh. Physiol. Biochem. (2006) 112(2):130-137.
7. BURTON PB, DANIEL TO: Anti-inflammatory strategies in coronary atherosclerosis. Curr. Opin. Investig. Drugs (2002) 3(12):1725-1728.
8. CARTER GW, YOUNG PR, ALBERT DH et al.: 5-Lipoxygenase inhibitory activity of zileuton. J. Pharmacol. Exp. Ther. (1991) 256(3):929-937.
9. CENTANNI S, SANTUS P: Antileukotrienes in clinical development for asthma. Expert Opin. Investig. Drugs (2002) 11(1):49-58.
10. RICCIONI G, DI ILIO C, D'ORAZIO N: An update of the leukotriene modulators for the treatment of asthma. Expert Opin. Investig. Drugs (2004) 13(7):763-776.
11. LAZARUS R, LEE T, KEMP JP: Safety and efficacy of zileuton in patients with chronic asthma. Am. J. Manag. Care (1998) 4:841-848.
12. PETERS-GOLDEN M: Cell biology of the 5-lipoxygenase pathway. Am. J. Respir. Crit. Care Med. (1998) 157(6 Part 2):S227-S231; discussion S231-S232, S247-S248.
13. BROCK TG, LEE YJ, MAYDANSKI E et al.: Nuclear localization of leukotriene A4 hydrolase in type II alveolar epithelial cells in normal and fibrotic lung. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) 289(2):L224-L232.
14. MURPHY RC, GIJON MA: Biosynthesis and metabolism of leukotrienes. Biochem. J. (2007) 405(3):379-395.
15. FOLCO G, MURPHY RC: Eicosanoid transcellular biosynthesis: from cell - cell interactions to in vivo tissue responses. Pharmacol. Rev. (2006) 58(3):375-388.
16. FEINMARK SJ, CANNON PJ: Vascular smooth muscle cell leukotriene C4 synthesis: requirement for transcellular leukotriene A4 metabolism. Biochim. Biophys. Acta (1987) 922(2):125-135.
17. FABRE JE, GOULET JL, RICHE E et al.: Transcellular biosynthesis contributes to the production of leukotrienes during inflammatory responses in vivo. J. Clin. Invest. (2002) 109(10):1373-1380.
18. BRINK C, DAHLEN SE, DRAZEN J et al.; INTERNATIONAL UNION OF PHARMACOLOGY XXXVII: Nomenclature for leukotriene and lipoxin receptors. Pharmacol. Rev. (2003) 55(1):195-227.
19. KANAOKA Y, BOYCE JA: Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol. (2004) 173(3):1503-1510.
20. NOREL X, BRINK C: The quest for new cysteinyl-leukotriene and lipoxin receptors: recent clues. Pharmacol. Ther. (2004) 103(1):81-94.
21. GILROY DW, LAWRENCE T, PERRETTI M, ROSSI AG: Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. (2004) 3(5):401-416.
22. SERHAN CN: Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Ann. Rev. Immunol. (2007) 25:101-137.
23. LEVY BD, CLISH CB, SCHMIDT B, GRONERT K, SERHAN CN: Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. (2001) 2(7):612-619.
24. FUNK CD: Leukotriene modifiers as potential therapeutics for cardiovascular disease. Nat. Rev. Drug Discov. (2005) 4(8):664-672.
25. ALLEN S, DASHWOOD M, MORRISON K, YACOUB M: Differential leukotriene constrictor responses in human atherosclerotic coronary arteries. Circulation (1998) 97(24):2406-2413.
26. SPANBROEK R, GRABNER R, LOTZER K et al.: Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc. Natl. Acad Sci. USA (2003) 100(3):1238-1243.
27. CIPOLLONE F, MEZZETTI A, FAZIA ML et al.: Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler. Thromb. Vasc. Biol. (2005) 25(8):1665-1670.
28. QIU H, GABRIELSEN A, AGARDH HE et al.: Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability. Proc. Natl. Acad. Sci. USA (2006) 103(21):8161-8166.
29. CARRY M, KORLEY V, WILLERSON JT, WEIGELT L, FORD-HUTCHINSON AW, TAGARI P: Increased urinary leukotriene excretion in patients with cardiac ischemia. In vivo evidence for 5-lipoxygenase activation. Circulation (1992) 85(1):230-236.
30. ALLEN SP SAMPSON AP, PIPER PJ, CHESTER AH, OHRI SK, YACOUB MH: Enhanced excretion of urinary leukotriene E4 in coronary artery disease and after coronary artery bypass surgery. Coron. Artery Dis. (1993) 4(10):899-904.
31. HELGADOTTIR A, MANOLESCU A, THORLEIFSSON G et al.: The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat. Genet. (2004) 36(3):233-239.
32. HELGADOTTIR A, MANOLESCU A, HELGASON A et al.: A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction. Nat. Genet. (2006) 38(1):68-74.
33. HELGADOTTIR A, GRETARSDOTTIR S, ST CLAIR D et al.: Association between the gene encoding 5-lipoxygenase-activating protein and stroke replicated in a Scottish population. Am. J. Hum. Genet. (2005) 76(3):505-509.
34. MAZNYCZKA A, MANGINO M, WHITTAKER A et al.: Leukotriene B4 production in healthy subjects carrying variants of the arachidonate 5-lipoxygenase-activating protein gene associated with a risk of myocardial infarction. Clin. Sci. (Lond.) (2007) 112(7):411-416.
35. ZEE RY, CHENG S, HEGENER HH, ERLICH HA, RIDKER PM: Genetic variants of arachidonate 5-lipoxygenase-activating protein, and risk of incident myocardial infarction and ischemic stroke: a nested case-control approach. Stroke (2006) 37(8):2007-2011.
36. KOCH W, HOPPMANN P, MUELLER JC, SCHOMIG A, KASTRATI A: No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population. Genet. Med. (2007) 9(2):123-129.
37. GIRELLI D, MARTINELLI N, TRABETTI E et al.: ALOX5AP gene variants and risk of coronary artery disease: an angiography-based study. Eur. J. Hum. Genet. (2007) 15(9):959-966.
38. DWYER JH, ALLAYEE H, DWYER KM et al.: Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N. Engl. J. Med. (2004) 350(1):29-37.
39. GONZALEZ P, REGUERO JR, LOZANO I, MORIS C, COTO E: A functional Sp1/ Egr1-tandem repeat polymorphism in the 5-lipoxygenase gene is not associated with myocardial infarction. Int. J. Immunogenet. (2007) 34(2):127-130.
40. MEHRABIAN M, WONG J, WANG X et al. Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ. Res. (2001) 89(2):125-130.
41. MEHRABIAN M, ALLAYEE H, WONG J et al.: Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ. Res. (2002) 91(2):120-126.
42. LYONS MA: Arachidonate 5-lipoxygenase variants in atherosclerosis, obesity, and bone traits. Circ. Res. (2006) 98(8):E66.
43. 1 in smooth muscle cell recruitment. Circulation (2005) 112(4):578-586.
44. SUBBARAO K, JALA VR, MATHIS S et al.: Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler. Thromb. Vasc. Biol. (2004) 24(2):369-375.
45. ZHAO, L, MOOS MP, GRABNER R et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm. Nat. Med. (2004) 10(9):966-973.
46. AIELLO RJ, BOURASSA PA, LINDSEY S, WENG W, FREEMAN A, SHOWELL HJ: Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler. Thromb. Vasc. Biol. (2002) 22(3):443-449.
47. BROOKS CD, SUMMERS JB: Modulators of leukotriene biosynthesis and receptor activation. J. Med. Chem. (1996) 39(14):2629-2654.
48. JULÉMONT F, DOGNÉ J-M, LAECKMANN D, PIROTTE B, LEVAL XD: Recent developments in 5-lipoxygenase inhibitors. Expert Opin. Ther. Patents (2003) 13(1):1-13.
49. POMMERY NM, MASSINGHAM R, ÉNICHART J-P: 5-Lipoxygenase inhibitors - patent and literature activity during 2001 - 2004. Expert Opin. Ther. Patents (2006) 16(1):13-26.
50. MCMILLAN RM, WALKER ER: Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol. Sci. (1992) 13(8):323-330.
51. JOSHI EM, HEASLEY BH, CHORDIA MD, MACDONALD TL: In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity. Chem. Res. Toxicol. (2004) 17(2):137-143.
52. REID JJ: ABT-761 (Abbott). Curr. Opin. Investig. Drugs (2001) 2(1):68-71.
53. CRAWLEY GC, BIRD TG, BRUNEAU P et al.: Structure and activity relationships leading to the discovery of ICI D2138, a selective, potent and orally active inhibitor of 5-lipoxygenase. J. Lipid Mediat. (1993) 6(1-3):249-257.
54. CRAWLEY GC, DOWELL RI, EDWARDS PN et al.: Methoxytetrahydropyrans. A new series of selective and orally potent 5-lipoxygenase inhibitors. J. Med. Chem. (1992) 35(14):2600-2609.
55. MCMILLAN RM, SPRUCE KE, CRAWLEY GC, WALKER ER, FOSTER SJ: Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase. Br. J. Pharmacol. (1992) 107(4):1042-1047.
56. NASSER SM, BELL GS, FOSTER S et al.: Effect of the 5-lipoxygenase inhibitor ZD2138 on aspirin-induced asthma. Thorax (1994) 49(8):749-756.
57. NASSER SM, BELL GS, HAWKSWORTH RJ et al.: Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. Thorax (1994) 49(8):743-748.
58. MANO T, STEVENS RW, ANDO K et al.: Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate. Chem. Pharm. Bull. (Tokyo) (2005) 53(8):965-973.
59. MANO T, STEVENS RW, ANDO K et al.: Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase. Bioorg Med. Chem. (2003) 11(18):3879-3887.
60. FISCHER L, SZELLAS D, RADMARK O, STEINHILBER D, WERZ O: Phosphorylation- and stimulus-dependent inhibition of cellular 5-lipoxygenase activity by nonredox-type inhibitors. FASEB J. (2003) 17(8):949-951.
61. WERZ O, STEINHILBER D: Development of 5-lipoxygenase inhibitors - lessons from cellular enzyme regulation. Biochem. Pharmacol. (2005) 70(3):327-333.
62. YOUNG RN, GILLARD JW, HUTCHINSON JH, LEGER S, PRASIT P: Discovery of inhibitors of the 5-lipoxygenase activating protein (flap). J. Lipid Mediat. (1993) 6(1-3):233-238.
63. VICKERS PJ: 5-Lipoxygenase-activating protein (FLAP). J. Lipid Mediat. Cell Signal. (1995) 12(2-3):185-194.
64. GILLARD J, FORD-HUTCHINSON AW, CHAN C et al.: L-663,536 (MK-886) (3-[1-(4-chlorobenzyl)-3-t-butyl-thio-5- isopropylindol-2-yl]-2,2-dimethylpropanoic acid), a novel, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. (1989) 67(5):456-464.
65. FRUCHTMANN R, MOHRS KH, HATZELMANN A et al.: In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Agents Actions (1993) 38(3-4):188-195.
66. BRIDEAU C, CHAN C, CHARLESON S et al.: Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)- 5-(quinolin-2-yl-methoxy)-indol-2-yl]- 2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor. Can. J. Physiol. Pharmacol. (1992) 70(6):799-807.
67. FRIEDMAN BS, BEL EH, BUNTINXA et al.: Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. Am. Rev. Respir. Dis. (1993) 147(4):839-844.
68. DIAMANT Z, TIMMERS MC, VAN DER VEEN H et al.: The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J. Allergy Clin. Immunol. (1995) 95(1 Part 1):42-51.
69. DAHLEN B, KUMLIN M, IHRE E, ZETTERSTROM O, DAHLEN SE: Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. Thorax (1997) 52(4):342-347.
70. HAMILTON AL, WATSON RM, WYILE G, O'BYRNE PM: Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005. Thorax (1997) 52(4):348-354.
71. HAKONARSON H, THORVALDSSON S, HELGADOTTIR A et al.: Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial. JAMA (2005) 293(18):2245-2256.
72. 4) hydrolase as potential anti-inflammatory agents. Curr. Pharm. Des. (2001) 7(3):163-179.
73. ASKONAS LJ, KACHUR JF, VILLANI-PRICE D, HANG CD, RUSSELL MA, SMITH WG: Pharmacological characterization of SC-57461A (3-[methyl[3-[4- (phenylmethyl)phenoxy] propyl]amino]- propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies. J. Pharmacol Exp. Ther. (2002) 300(2):577-582.
74. CHEN X, WANG S, WU N, YANG CS: Leukotriene A4 hydrolase as a target for cancer prevention and therapy. Curr. Cancer Drug Targets (2004) 4(3):267-283.
75. SANDANAYAKA V, MAMAT B, YU P et al.: DG-051: A novel leukotriene A4 hydrolase inhibitor for the treatment of myocardial infarction and stroke. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States (25-29 March 2007).
76. RAO NL, DUNFORD PJ, XUE X et al.: Anti-inflammatory activity of a potent, selective leukotriene A4 hydrolase inhibitor in comparison with the 5-lipoxygenase inhibitor zileuton. J. Pharmacol. Exp. Ther. (2007) 321(3):1154-1160.
77. SHOWELL HJ, CONKLYN MJ, ALPERT R et al.: The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543. J. Pharmacol. Exp. Ther. (1998) 285(3):946-954.
78. 4 antagonists in the mouse ear edema and rat neutropenia models. Inflamm. Res. (1995) 44(Suppl. 2):S141-S142.
79. 4 receptor antagonist with anti-inflammatory activity. Prostaglandins Leukot. Essent. Fatty Acids (1999) 61(1):55-64.
80. SOFIA MJ, FLOREANCIG P, BACH N et al.: The discovery of LY293111, a novel, potent and orally active leukotriene B4 receptor antagonist of the biphenylphenol class. Adv. Exp. Med. Biol. (1997) 400A:381-386.
81. BIRKE FW, MEADE CJ, ANDERSKEWITZ R, SPECK GA, JENNEWEIN HM: In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J. Pharmacol. Exp. Ther. (2001) 297(1):458-466.
82. DIAZ-GONZALEZ F, ALTEN RH, BENSEN WG et al.: Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann. Rheum. Dis. (2007) 66(5):628-632.
83. 4 receptor antagonist, in patients with advanced solid tumors. J. Clin. Oncol. (2005) 23(23):5365-5373.
84. KIKAWA Y, MIYANOMAE T, INOUE Y et al.: Urinary leukotriene E4 after exercise challenge in children with asthma. J. Allergy Clin. Immunol. (1992) 89(6):1111-1119.
85. FINNERTY JP, WOOD-BAKER R, THOMSON H, HOLGATE ST: Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am. Rev. Respir. Dis. (1992) 145(4 Part 1):746-749.
86. DAHLEN B, MARGOLSKEE DJ, ZETTERSTROM O, DAHLEN SE: Effect of the leukotriene receptor antagonist MK-0679 on baseline pulmonary function in aspirin sensitive asthmatic subjects. Thorax (1993) 48(12):1205-1210.
87. JAWIEN J, NASTALEK P, KORBUT R: Mouse models of experimental atherosclerosis. J. Physiol. Pharmacol. (2004) 55(3):503-517.
88. SCHWARTZ SM, GALIS ZS, ROSENFELD ME, FALK E: Plaque rupture in humans and mice. Arterioscler. Thromb. Vasc. Biol. (2007) 27(4):705-713.
89. JACKSON CL, BENNETT MR, BIESSEN EA, JOHNSON JL, KRAMS R: Assessment of unstable atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. (2007) 27(4):714-720.
90. FRITSCHE-DANIELSON R, WÅGBERG M, GAN L-M, MCPHEAT WL: 5-Lipoxygenase inhibition slows lesion progression in the aorta of LDLr KO mice as assessed by in vivo ultrasound biomicroscopy. International Atherosclerosis Society Meeting, Rome, Italy (2006).
91. VIDAL C, GOMEZ-HERNANDEZ A, SANCHEZ-GALAN E et al.: Licofelone, a balanced inhibitor of cyclooxygenase and 5-lipoxygenase, reduces inflammation in a rabbit model of atherosclerosis. J. Pharmacol. Exp. Ther. (2007) 320(1):108-116.
92. JAWIEN J, GAJDA M, RUDLING M et al.: Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur. J. Clin. Invest. (2006) 36(3):141-146.
93. GOJOVA A, BRUN V, ESPOSITO B et al.: Specific abrogation of transforming growth factor-β signaling in T cells alters atherosclerotic lesion size and composition in mice. Blood (2003) 102(12):4052-4058.
94. ROBERTSON AK, RUDLING M, ZHOU X, GORELIK L, FLAVELL RA, HANSSON GK: Disruption of TGF-β signaling in T cells accelerates atherosclerosis. J. Clin. Invest. (2003) 112(9):1342-1350.
95. BACK M, SULTAN A, OVCHINNIKOVA O, HANSSON GK: 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ. Res. (2007) 100(7):946-949.
96. ROSSONI G, SALA A, BERTI F et al.: Myocardial protection by the leukotriene synthesis inhibitor BAY X1005: importance of transcellular biosynthesis of cysteinyl-leukotrienes. J. Pharmacol. Exp. Ther. (1996) 276(1):335-341.
97. HORSTMANN R, BECKERMANN B, BOETTCHER M et al.: Clinical pharmacological investigations with the new leukotriene synthesis inhibitor BAYX1005. Am. J. Respir. Crit. Care Med. (1994) 149:A465.
98. O'BYRNE PM, WATSON RM, STRONG HA, WYILE G: The effect of treatment with a 5-lipoxygenase inhibitor BAY x1005 on allergen-induced asthmatic responses in human subjects. Am. J. Respir. Crit. Care Med. (1994) 149:A532.
99. LICHEY J, HUMMEL S, BECK E, ULBRICH E: Effects of leukotriene antagonist BAY x1005 versus placebo in patients with severe steroid dependent bronchial asthma. Am. J. Respir. Crit. Care Med. (1995) 151:A377.
100. VIRCHOW JC, NOLLER PS, WIEBMANN KJ et al.: Multicenter trial of BAY x1005, a new 5-lipoxygenase activating protein (FLAP) inhibitor in the treatment of chronic asthma. Am. J. Respir. Crit. Care Med. (1995) 151:A377.
101. O'DONNELL CJ: Translating the human genome project into prevention of myocardial infarction and stroke - getting close? JAMA (2005) 293(18):2277-2279.
102. THUNNISSEN MM, NORDLUND P, HAEGGSTROM JZ: Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat. Struct. Biol. (2001) 8(2):131-135.
103. THUNNISSEN MM, ANDERSSON B, SAMUELSSON B, WONG CH, HAEGGSTROM JZ: Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J. (2002) 16(12):1648-1650.
104. NISSEN SE, NICHOLLS SJ, SIPAHI I et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA (2006) 295(13):1556-1565.
105. GABER F, JAMES A, DELIN I et al.: Assessment of in vivo 5-lipoxygenase activity by analysis of leukotriene B4 in saliva: effects of treatment with zileuton. J. Allergy Clin. Immunol. (2007) 119(5):1267-1268.
106. KLOTSMAN M, YORK TP, PILLAI SG et al.: Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet. Genomics (2007) 17(3):189-196.